Table 1.
Baseline characteristics at cumulative doxorubicin dose < 200 and ≥ 200 mg m− 2
| Cumulative Doxorubicin dose (mg m− 2) | ||||
|---|---|---|---|---|
| All patients | < 200 | ≥200 | P-value | |
| N (%) | 35 | 14 (40%) | 21 (60%) | |
| Age (year) | 50.6 ± 13.2 | 50.3 ± 13.4 | 50.8 ± 13.4 | NS |
| Female (%) | 14 (40.0%) | 5 (14.2%) | 9 (25.8%) | NS |
| White (%) | 21 (60.0%) | 11 (31.4%) | 10 (28.6%) | NS |
| Hyperlipidemia | 18 (51.4%) | 5 (14.3%) | 13 (37%) | NS |
| Diabetes | 19 (54.2%) | 10 (28.6%) | 9 (27.5%) | NS |
| Hypertension | 27 (77.14%) | 11 (31.4%) | 16 (45.7%) | NS |
| Smoker (%) | 13 (37.1%) | 5 (14.3%) | 8 (22.9%) | NS |
| COPD (%) | 3 (0.9%) | 2 (0.6%) | 1 (0.3%) | NS |
| Heart rate (bpm) | 89.1 ± 14.2 | 92.8 ± 17.2 | 86.6 ± 11.5 | NS |
| BMI | 27.9 ± 5.6 | 28.1 ± 5.7 | 27.8 ± 5.7 | NS |
BMI Body Mass Index, bpm beats per minute, COPD chronic obstructive pulmonary disease